LL-37 5mg

Description:

LL-37 peptide, also known as human cathelicidin antimicrobial peptide (hCAP-18), is a naturally occurring antimicrobial peptide found in humans. It is derived from the C-terminal region of the cathelicidin protein. LL-37 is composed of 37 amino acid residues and has a unique sequence that gives it its antimicrobial properties.
LL-37 is a broad-spectrum antimicrobial peptide, meaning it has the ability to kill a wide range of microorganisms, including bacteria, viruses, and fungi. It is particularly effective against both gram-positive and gram-negative bacteria, including drug-resistant strains like MRSA and VRE.

In addition to its antimicrobial properties, LL-37 has other important functions in the immune system. It can modulate the immune response by promoting the recruitment and activation of immune cells, such as monocytes, macrophages, and T cells. LL-37 also has the ability to stimulate wound healing and promote angiogenesis, the formation of new blood vessels.

LL-37 Research:

Research involving LL-37 peptide is still ongoing, and scientists are exploring its potential applications in various areas, including:

• Infectious diseases: LL-37 has been investigated as a potential therapeutic agent against bacterial, fungal, and viral infections. Its antimicrobial properties make it an attractive candidate for developing new antimicrobial drugs.
• Inflammatory diseases: LL-37 has been shown to have immunomodulatory effects, and it may play a role in regulating the inflammatory response. Researchers are studying its potential use in treating inflammatory conditions such as psoriasis, acne, and inflammatory bowel disease.
• Wound healing: LL-37 has been found to promote wound healing by enhancing the migration and proliferation of cells involved in the healing process. It may also have antimicrobial effects that can prevent infections in wounds.
• Cancer: Some studies have suggested that LL-37 may have anticancer properties. It has been shown to inhibit the growth of certain cancer cells and promote apoptosis (programmed cell death) in tumor cells. However, more research is needed to fully understand its potential in cancer treatment.
• Therapeutic Potential: Due to its involvement in the inflammatory processes of rheumatoid arthritis, LL-37 has been considered a potential target for therapeutic intervention. Researchers have explored the use of inhibitors or neutralizing agents against LL-37 to mitigate its pro-inflammatory effects in arthritis.